Inhibition of angiopoietin 2 attenuates lumen formation of tumour-associated vessels in vivo

Suzuki,Rei; Yamamoto,Hirofumi; Ngan,Chew  Yee; Ohtsuka,Masahisa; Kitani,Kotaro; Uemura,Mamoru; Nishimura,Junichi; Takemasa,Ichiro; Mizushima,Tsunekazu; Sekimoto,Mitsugu; Minamoto,Toshinari; Doki,Yuichiro; Mori,Masaki

doi:10.3892/ijo.2013.2076

Inhibition of angiopoietin 2 attenuates lumen formation of tumour-associated vessels in vivo

Authors:
- Rei Suzuki
- Hirofumi Yamamoto
- Chew Yee Ngan
- Masahisa Ohtsuka
- Kotaro Kitani
- Mamoru Uemura
- Junichi Nishimura
- Ichiro Takemasa
- Tsunekazu Mizushima
- Mitsugu Sekimoto
- Toshinari Minamoto
- Yuichiro Doki
- Masaki Mori
View Affiliations

Affiliations: Department of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan, Division of Translational and Clinical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan
Published online on: August 23, 2013 https://doi.org/10.3892/ijo.2013.2076
Pages: 1447-1455

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anti-angiogenic therapy, inhibition of a co-operative process with vascular endothelial cells and pericytes could be an effective strategy to treat malignant tumours. Apart from vascular endothelial growth factor (VEGF), angiopoietin 2 (Ang2) is a promising target of anti-angiogenic therapy. Although inhibition of Ang2 has been shown to decrease tumour size in preclinical and phase I trials, its mechanisms of action remain largely unknown. To elucidate the mechanisms of Ang2 inhibition, we have focused on differentiation of the vessels as well as on growth of the vessels, especially in vivo. L1-10, a selective Ang2 inhibitor was used. The in vitro effects of Ang2 inhibition or addition of Ang2 using HUVECs were also examined. Growth and differentiation of tumour-associated vessels were investigated in xenografts derived from a colon cancer treated by L1-10. Effects of VEGF inhibition were also examined to discriminate Ang2-specific action on the tumour-associated vessels. In vitro studies showed that VEGF enhanced proliferation and tube formation of HUVECs, and caused a significant increase in Rac1 and CDC42 expression when cultured in the collagen matrix gel, whereas neither Ang2 nor L1-10 affected in vitro behaviour of HUVECs or levels of the proteins. In vivo, on the other hand, we found that Ang2 inhibition with treatment of L1-10 dose‑dependently decreased tumour growth. Furthermore, we found that L1-10 treatment extends the tumour-associated vessels whilst it suppressed a sound lumen formation. Histological analysis on xenografts suggests that Ang2 inhibition could have disturbed in vivo vascular differentiation. Our data provide a novel aspect that Ang2 may play an essential role in in vivo vascular differentiation, thus supporting a rationale for Ang2-targeted therapy against colon cancer.

View Figures

View References

1.	Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003. View Article : Google Scholar
2.	Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 21:60–65. 2003. View Article : Google Scholar
3.	Ogawa M, Yamamoto H, Nagano H, et al: Hepatic expression of ANG2 RNA in metastatic colorectal cancer. Hepatology. 39:528–539. 2004. View Article : Google Scholar : PubMed/NCBI
4.	Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
5.	Maisonpierre PC, Suri C, Jones PF, et al: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 277:55–60. 1997. View Article : Google Scholar : PubMed/NCBI
6.	Suri C, Jones PF, Patan S, et al: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 87:1171–1180. 1996. View Article : Google Scholar : PubMed/NCBI
7.	Oliner J, Min H, Leal J, et al: Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell. 6:507–516. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Brown JL, Cao ZA, Pinzon-Ortiz M, et al: A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther. 9:145–156. 2010. View Article : Google Scholar
9.	Coxon A, Bready J, Min H, et al: Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther. 9:2641–2651. 2010. View Article : Google Scholar : PubMed/NCBI
10.	Falcon BL, Hashizume H, Koumoutsakos P, et al: Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol. 175:2159–2170. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM and Fidler IJ: Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res. 48:6863–6871. 1988.PubMed/NCBI
12.	Yamamoto H, Kondo M, Nakamori S, et al: JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1. Gastroenterology. 125:556–571. 2003.PubMed/NCBI
13.	Morrissey C, Dowell A, Koreckij TD, et al: Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability. Prostate. 70:1799–1808. 2010.PubMed/NCBI
14.	Tressel SL, Kim H, Ni CW, et al: Angiopoietin-2 stimulates blood flow recovery after femoral artery occlusion by inducing inflammation and arteriogenesis. Arterioscler Thromb Vasc Biol. 28:1989–1995. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Bayless KJ and Davis GE: The Cdc42 and Rac1 GTPases are required for capillary lumen formation in three-dimensional extracellular matrices. J Cell Sci. 115:1123–1136. 2002.PubMed/NCBI
16.	Davis GE, Bayless KJ and Mavila A: Molecular basis of endothelial cell morphogenesis in three-dimensional extracellular matrices. Anat Rec. 268:252–275. 2002. View Article : Google Scholar : PubMed/NCBI
17.	Folkman J and Haudenschild C: Angiogenesis in vitro. Nature. 288:551–556. 1980. View Article : Google Scholar
18.	Bayless KJ, Salazar R and Davis GE: RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. Am J Pathol. 156:1673–1683. 2000. View Article : Google Scholar
19.	Davis GE and Bayless KJ: An integrin and Rho GTPase-dependent pinocytic vacuole mechanism controls capillary lumen formation in collagen and fibrin matrices. Microcirculation. 10:27–44. 2003. View Article : Google Scholar
20.	Yang S, Graham J, Kahn JW, Schwartz EA and Gerritsen ME: Functional roles for PECAM-1 (CD31) and VE-cadherin (CD144) in tube assembly and lumen formation in three-dimensional collagen gels. Am J Pathol. 155:887–895. 1999. View Article : Google Scholar : PubMed/NCBI
21.	Kamei M, Saunders WB, Bayless KJ, Dye L, Davis GE and Weinstein BM: Endothelial tubes assemble from intracellular vacuoles in vivo. Nature. 442:453–456. 2006. View Article : Google Scholar : PubMed/NCBI
22.	Hashizume H, Falcon BL, Kuroda T, et al: Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res. 70:2213–2223. 2010. View Article : Google Scholar : PubMed/NCBI
23.	Huang H, Lai JY, Do J, et al: Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin Cancer Res. 17:1001–1011. 2011. View Article : Google Scholar : PubMed/NCBI
24.	Chae SS, Kamoun WS, Farrar CT, et al: Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res. 16:3618–3627. 2010. View Article : Google Scholar : PubMed/NCBI
25.	Herynk MH, Tsan R, Radinsky R and Gallick GE: Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin. Clin Exp Metastasis. 20:291–300. 2003. View Article : Google Scholar : PubMed/NCBI
26.	Kim Y, Park H, Lim Y, et al: Decreased syndecan-2 expression correlates with trichostatin-A induced-morphological changes and reduced tumorigenic activity in colon carcinoma cells. Oncogene. 22:826–830. 2003. View Article : Google Scholar
27.	Shim WS, Ho IA and Wong PE: Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res. 5:655–665. 2007. View Article : Google Scholar : PubMed/NCBI
28.	Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI